Highly ranked Journal of Alzheimer's Disease to publish two DiaGenic ADtect® articles

Highly ranked Journal of Alzheimer's Disease to publish two DiaGenic

ADtect® articles

Abstracts of two articles to be published in the highly ranked Journal

of Alzheimer's Disease have been posted today on the journal's web site.

This will build confidence in ADtect® among clinicians and

pharmaceutical companies and confirm DiaGenic's leading position as a

provider of biomarkers in the CNS field.

The article "A Gene Expression Pattern in Blood for the Early Detection

of Alzheimer's Disease" discusses the identification and validation of a

gene expression signature in blood that classifies AD patients and

cognitively healthy controls with high accuracy. The study is based on a

Whole Genome Study in Alzheimer patients and healthy controls. The

article shows that Alzheimer's disease can be detected distant from the

site of the disease with the aid of gene expression.

The second article "A Novel Blood Test for the Early Detection of

Alzheimer's Disease" discusses the CE studies on ADtect® and the results

from extensive validations of ADtect®. The study provides documentation

of the robustness of ADtect® and discusses the accuracy of the test.

Assuming a clinical accuracy of 80%, statistical modelling indicates

that the agreement with underlying true pathology is in the range

85%-90%. 32 genes of the 96 gene signature of the test are associated

with known AD pathology and supports that ADtect measures changes

related to the disease. These findings support that the gene expression

blood test can aid in the diagnosis of mild to moderate AD.

"Journal of Alzheimer's Disease is the most prolific and highly cited

journal in the Alzheimer's disease field. Therefore we are extremely

satisfied having two articles accepted by the journal discussing

ADtect®. This will build confidence among clinicians and pharma

companies and confirms our position as a leading provider of blood based

gene expression biomarkers in the CNS field", says Erik Christensen MD

PhD, CEO of DiaGenic.

The abstract of the articles can be found at:

http://www.j-alz.com/issues/23/vol23-1.html (http://www.j-alz.com/issues

/23/vol23-1.html) . Once published, both articles will be available at

DiaGenic's web site: www.diagenic.com (http://www.diagenic.com/).

Contact:

Erik Christensen, CEO

Telephone: 47 95939918

AI Terminal